Clinical trials
Ovarian Diseases clinical trials
Below are recruiting ovarian diseases clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT06180356RecruitingPhase 2
Niraparib after surgery for ovarian cancer with limited spread
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
A CoruñaAges 18 years+ - NCT06760923Recruiting
Urine test for ovarian cancer detection and tracking
This study looks at proteins in urine to help find ovarian cancer earlier and track how the disease changes. It aims to provide a non-invasive way to tell the difference between benign and malignant pelvic masses.
Changsha, HunanAges 18 years+ - NCT06339489Recruiting
Bone Health in Early Menopause Study
This study looks at how bone health changes in women with premature ovarian insufficiency (early menopause). It aims to understand the body's bone metabolism to help manage long-term health.
BeijingAges 18–39 - NCT06083844RecruitingPhase 2
Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
New York, New YorkAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06583395Enrolling by invitation
Meditation retreat study with fitness tracker
This trial studies people attending a 7-day meditation retreat to see how meditation affects well-being. You will wear a fitness tracker and answer surveys.
Palm Desert, CaliforniaAges 21 years+ - NCT02754115Recruiting
Audit of surgery with heated chemo for belly tumors
This study is an audit (a review of care) of patients who undergo cytoreductive surgery plus heated chemotherapy placed in the abdomen. It helps doctors understand how this treatment is done and what outcomes and safety it has.
Mumbai, MaharashtraAges 18–70 - NCT07392216Recruiting
Ovarian health in young women with sickle cell disease
This study looks at how sickle cell disease might affect the ovaries (the organs that store eggs) in girls and young women. It compares participants with sickle cell disease to healthy females of similar age and background.
Memphis, TennesseeAges 10–18 - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT06392997Recruiting
Saliva test for gynecologic conditions before surgery
This study is testing a simple saliva sample to see if it can help detect gynecologic conditions (like endometriosis, fibroids, or ovarian/uterine/cervical cancer) before or during surgery. If you are having surgery or a biopsy for one of these issues, your saliva may help improve diagnosis.
AngersAges 18 years+ - NCT07043322RecruitingPhase 2
Cabergoline vs coasting for OHSS prevention
This study tests whether a medicine called cabergoline can lower the chance of ovarian hyperstimulation syndrome (OHSS) in women undergoing IVF who are at high risk. It compares cabergoline with a standard technique called 'coasting' (stopping fertility drugs for a few days).
Damietta, New DamiettaAges 20–35 - NCT06962059Recruiting
Healthy volunteers with ovaries needed for study
This study is looking for healthy volunteers who still have their ovaries and have not had cancer or certain genetic mutations. Researchers want to learn more about ovarian health.
Philadelphia, PennsylvaniaAges 30–50 - NCT07167433Recruiting
Observational study of ovarian cancer from 2021 onward
This study looks at the real-world experiences of patients with ovarian cancer, whether newly diagnosed or with persistent or recurrent disease. It aims to learn more about the disease and its treatment over time.
Barretos/SPAges 18 years+ - NCT05875155Recruiting
Saving eggs by freezing ovarian tissue during cancer or surgery care
This trial looks at freezing ovarian tissue to help protect future fertility for people who may lose ovarian function from medical treatments or ovarian surgery. It may help you preserve the chance to have children later when egg or embryo freezing alone isn’t an option.
Pittsburgh, PennsylvaniaAges Up to 39 years - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT05567198Recruiting
Testing hormone shots to protect ovaries during lupus chemotherapy
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Bethesda, MarylandAges 18–120 - NCT07546123Recruiting
Freezing Ovarian Tissue and Eggs for Cancer Patients
This trial compares two methods of preserving a woman's fertility before cancer treatment: freezing eggs alone versus freezing both eggs and ovarian tissue. The goal is to help women who may lose fertility due to chemotherapy or radiation keep their options open for having biological children in the future.
Bologna, BolognaAges 18–46 - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT06682988RecruitingPhase 2
New treatment for advanced ovarian cancer
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Sarasota, FloridaAges 18 years+ - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT06203106Recruiting
NYSCF Scientific Discovery Biobank
This study collects blood, saliva, or skin samples from people with certain neurological conditions and from healthy volunteers to help researchers better understand and find treatments for these diseases.
New York, New YorkAges 4 weeks+
Hear when a new Ovarian Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian diseases?
- Yes. Clin2 currently lists 29 recruiting ovarian diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.